Helen E. Godonis
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Neurotransmitter Receptor Influence on Behavior, Neuroscience and Neuropharmacology Research, Pancreatic function and diabetes, Receptor Mechanisms and Signaling, Pharmacology and Obesity Treatment
Most-Cited Works
- → Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats(2012)212 cited
- → Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated(2002)59 cited
- → Anxiolytic-Like Effects of the Corticotropin-Releasing Factor1 (CRF1) Antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] Administered Acutely or Chronically at Doses Occupying Central CRF1 Receptors in Rats(2004)55 cited
- → Identification of a Nonbasic Melanin Hormone Receptor 1 Antagonist as an Antiobesity Clinical Candidate(2014)20 cited
- → Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2- d ]pyrimidin-4(3 H )-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor(2016)15 cited
- → Non-basic azolotriazinone MCHR1 antagonists for the treatment of obesity: An empirical brain-exposures-driven candidate selection for in vivo efficacy studies(2015)15 cited
- → Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties(2013)11 cited
- → Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup(2015)8 cited
- → DMP 504, a novel hydrogel bile acid sequestrant: II. Lipid-lowering pharmacology in the hamster(1997)6 cited
- → DMP 504, a novel hydrogel bile acid sequestrant: II. Lipid‐lowering pharmacology in the hamster(1997)